ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.

Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked venous thromboembolism.

This single-center, randomized, double-blind, placebo-controlled study enrolled 600 patients who completed at least 3 months of standard therapeutic anticoagulation following provoked VTE, randomizing them 1:1 to receive apixaban 2.5mg twice daily or placebo for 12 months. Primary endpoints include symptomatic recurrent VTE and ISTH major bleeding at 12 months, providing crucial data for optimizing long-term anticoagulation strategies in this underserved patient population.

Findings showed that apixaban reduced recurrence in at-risk patients with provoked venous thromboembolism by 87%, with a low risk of major bleeding.

Interview Questions:

1. What is the importance of HI-PRO?
2. Could you tell us about the study design and patient population?
3. What were the key findings from the trial?
4. What is the potential clinical impact of these findings?
5. How should these findings impact future guideline reccomendations?
6. What is your key take-home message for clinicians?
7. What are the next steps?

Recorded on-site at ESC Congress 2025, Madrid.

Editors: Jordan Rance, Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Vascular.